775 related articles for article (PubMed ID: 11059779)
41. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
42. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
43. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
Eder IE; Haag P; Basik M; Mousses S; Bektic J; Bartsch G; Klocker H
Mol Carcinog; 2003 Aug; 37(4):181-91. PubMed ID: 12891627
[TBL] [Abstract][Full Text] [Related]
44. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
45. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
[TBL] [Abstract][Full Text] [Related]
46. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action.
Bigler D; Gulding KM; Dann R; Sheabar FZ; Conaway MR; Theodorescu D
Oncogene; 2003 Feb; 22(8):1261-72. PubMed ID: 12606954
[TBL] [Abstract][Full Text] [Related]
47. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
[TBL] [Abstract][Full Text] [Related]
48. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
49. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
50. The atypical GATA protein TRPS1 represses androgen-induced prostate-specific antigen expression in LNCaP prostate cancer cells.
van den Bemd GJ; Jhamai M; Brinkmann AO; Chang GT
Biochem Biophys Res Commun; 2003 Dec; 312(3):578-84. PubMed ID: 14680804
[TBL] [Abstract][Full Text] [Related]
51. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
52. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
[TBL] [Abstract][Full Text] [Related]
53. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
54. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
55. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
56. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Arnold JT; Liu X; Allen JD; Le H; McFann KK; Blackman MR
Prostate; 2007 Aug; 67(11):1152-62. PubMed ID: 17503469
[TBL] [Abstract][Full Text] [Related]
57. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
Wang LG; Liu XM; Kreis W; Budman DR
Cancer Res; 1997 Feb; 57(4):714-9. PubMed ID: 9044850
[TBL] [Abstract][Full Text] [Related]
58. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
59. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
[TBL] [Abstract][Full Text] [Related]
60. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways.
Sadar MD
J Biol Chem; 1999 Mar; 274(12):7777-83. PubMed ID: 10075669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
